A review on the use of Ganaxolone in the treatment of Epilepsy

Abstract

Epilepsy currently affects about 50 million people and approximately 10% of the population will have at least one seizure during their lifetime yet very little is known about this condition. This condition can occur as a result of various causes and has multiple proposed pathogenesis. There are multiple types of epilepsy and as of now there is no cure. Even treatment for many types of epilepsy is not available. Ganaxolone is a new anti-seizure medication which has been approved by the USFDA for the treatment for CDD associated epilepsy, it is a first drug in its class. It has shown great promise in the clinical trials as it is effective against treatment resistant epilepsy and exhibits lower side effects and drug interactions. In this review, the clinical trial data of ganaxolone is analyzed and an evaluation of its effectiveness over currently available treatment is provided which can be used to unravel the full potential of this drug in the future.